TEST:

Lunit SCOPE IO

"Lunit...today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit’s AI-powered digital pathology technologies—Lunit SCOPE IO® and Lunit SCOPE® uIHC—can advance precision oncology by uncovering predictive immune signatures and guiding antibody-based drug development."

Residual TNBCs after standard NAC were predominantly basal-like or MES/BLIS subtypes with variable tumor microenvironment (TME). Early recurrence was associated with immune-cold TME, and further analyses on each treatment arm will provide deeper insights into the role of adjuvant immunotherapy.

The combination of IMAGiC and iTILs as a biomarker can guide clinical decisions in the immunotherapy of metastatic TNBCs.

Notably, incorporating TSR and CAF density with traditional high-risk criteria allowed for the reclassification of additional patients as high-risk, significantly improving DFS prediction and reducing false-negative rates. These findings highlight the potential of integrating AI-based histopathological analysis into routine clinical practice to enhance diagnostic precision, improve risk stratification, and ultimately optimize patient management in CRC.

"Lunit...has entered into a partnership with the Society for Immunotherapy of Cancer (SITC). This collaboration will launch the 'Lunit Research Program' for SITC members, granting access to Lunit SCOPE® IO for quantitative immune phenotyping and tumor microenvironment (TME) analysis from H&E whole slide images (WSIs)."

This study suggests that AI-MR analysis at the WSI level may serve as a valuable and unexpected complement to traditional HPF-based MR evaluations by pathologists in liposarcoma cases.

P2 | N=157 | NCT02721732 | "The findings indicate that Lunit SCOPE IO could effectively identify specific patterns in tumor samples that correlate with better treatment outcomes...Key findings from the study include: In certain tumor types, patients with higher pre-treatment iTIL density showed a 51% lower risk of disease progression or death (improved progression-free survival, PFS; HR: 0.49); Patients who had greater iTIL density increase at on-treatment biopsy showed a 35% lower risk of disease progression or death (HR: 0.65) and a 41% lower risk of death (improved overall survival, OS; HR: 0.59); Patients with greater tumor content decrease at on-treatment biopsy had a 49% lower risk of disease progression or death (HR: 0.51) and a 46% lower risk of death (HR: 0.54)."

"Lunit said...that it would present one of the latest studies using its AI biomarker platform, Lunit Scope, at the Society for Immunotherapy of Cancer 2024 (SITC 2024) in Houston, Texas, from Nov. 6 to 10...Lunit will present a study on AI-enabled immuno-oncology treatment response prediction in patients with various cancer types, including rare cancers."

All participants provided informed consent before taking part in the study. View this table:View inline View popup Download powerpoint Abstract 1207 Table 1 Patients' demographicsDownload figure Open in new tab Download powerpoint Abstract 1207 Figure 1 iTIL by histology and association with PFSDownload figure Open in new tab Download powerpoint Abstract 1207 Figure 2 Association of PFS and OS with post-treatment changes in iTIL and TCDownload figure Open in new tab Download powerpoint Abstract 1207 Figure 3 Association of PFS and OS with combination of both post-treatment increase in iTIL and decrease in TC

AI-powered spatial analysis suggests that combination therapy with Pexa-vec and cemiplimab enhances the immune response, evidenced by increased TIL densities in the tumor microenvironment.

P=NA | N=339 | "Lunit...announced that Lunit SCOPE IO has demonstrated significant potential in predicting immunotherapy response for patients with advanced biliary tract cancer (BTC), via AI-powered analysis of immune phenotype and tumor-infiltrating lymphocytes (TILs). The groundbreaking study, conducted in collaboration with researchers from Asan Medical Center and Severance Hospital in Seoul, Korea, was recently published in Clinical Cancer Research (CCR), an AACR journal...Key findings include...The inflamed group demonstrated both longer overall survival (12.6 vs. 5.1 months) and progression-free survival (4.5 vs. 1.9 months), as well as higher overall response rates (27.5% vs. 7.7%)....Lunit SCOPE IO provided objective and efficient assessment of the tumor microenvironment, overcoming limitations of manual evaluation demonstrating high feasibility for AI-powered analysis of immune phenotype and TIL."

Within the same immune microenvironment group, significant differences in immune metrics and T cell composition were observed according to molecular subtype. AI-based immune microenvironment groups served as prognostic markers in ECs, with the immune-active group associated with favorable outcomes.